Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Clinical trial NCT01237873 · COMPLETED

Trial details

NCT number: NCT01237873
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Essential Hypertension

Start date: 2011-01-01
Primary completion: 2012-02-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.